Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Regulus Therapeutics target lowered to $6 from $8 at Wedbush after adjusting launch timing for RG-012; Shares are undervalued as program updates and pipeline progress make 2017 a catalysts rich year (1.10)</td> </tr></table>"